MTOR Signaling Pathway and MTOR Inhibitors in Cancer: Progress and Challenges

Overview

Journal Cell Biosci

Publisher Biomed Central

Specialty Biology

Date 2020 Mar 17

PMID 32175074

Citations 347

Authors

Zhilin Zou

Tao Tao

Hongmei Li

Xiao Zhu

Affiliations

Soon will be listed here.

Abstract

Mammalian target of rapamycin (mTOR) regulates cell proliferation, autophagy, and apoptosis by participating in multiple signaling pathways in the body. Studies have shown that the mTOR signaling pathway is also associated with cancer, arthritis, insulin resistance, osteoporosis, and other diseases. The mTOR signaling pathway, which is often activated in tumors, not only regulates gene transcription and protein synthesis to regulate cell proliferation and immune cell differentiation but also plays an important role in tumor metabolism. Therefore, the mTOR signaling pathway is a hot target in anti-tumor therapy research. In recent years, a variety of newly discovered mTOR inhibitors have entered clinical studies, and a variety of drugs have been proven to have high activity in combination with mTOR inhibitors. The purpose of this review is to introduce the role of mTOR signaling pathway on apoptosis, autophagy, growth, and metabolism of tumor cells, and to introduce the research progress of mTOR inhibitors in the tumor field.

Citing Articles

Morpholine-Substituted Tetrahydroquinoline Derivatives as Potential mTOR Inhibitors: Synthesis, Computational Insights, and Cellular Analysis.

Dey R, Shaw S, Yadav R, Patel B, Bhatt H, Natesan G Cancers (Basel). 2025; 17(5).

PMID: 40075606 PMC: 11898650. DOI: 10.3390/cancers17050759.

Targeting EGFR and PI3K/mTOR pathways in glioblastoma: innovative therapeutic approaches.

Singh G, Rohit , Kumar P, Aran K Med Oncol. 2025; 42(4):97.

PMID: 40064710 DOI: 10.1007/s12032-025-02652-1.

Unveiling the Role of the Cellular Tumor Microenvironment and the Therapeutic Targets it Provides in Cutaneous T-Cell Lymphoma.

Chinas N, Kaliampou S, Nikolaou V Curr Oncol Rep. 2025; .

PMID: 40055269 DOI: 10.1007/s11912-025-01646-6.

Identification and differential expression analysis of microRNAs in the liver and spleen tissues of Yunnan Zebu and Holstein cattle.

Liu R, Liu H, Li R, Li C, Xiao H, Chen S Trop Anim Health Prod. 2025; 57(2):96.

PMID: 40038148 DOI: 10.1007/s11250-025-04357-z.

Frontiers and Controversies in De Novo Gastrointestinal Tumors After Organ Transplantation: Current Progress and Future Directions.

Xu X, Zhang S, Luo Z, Zheng Y, Kong T, Huang C Ann Surg Oncol. 2025; .

PMID: 40035907 DOI: 10.1245/s10434-025-16975-w.

References

Motzer R, Hutson T, Glen H, Michaelson M, Molina A, Eisen T . Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015; 16(15):1473-1482. DOI: 10.1016/S1470-2045(15)00290-9. View

Sun Y, Ai J, Jin X, Liu L, Lin T, Xu H . IL-8 protects prostate cancer cells from GSK-3β-induced oxidative stress by activating the mTOR signaling pathway. Prostate. 2019; 79(10):1180-1190. DOI: 10.1002/pros.23836. View

Roldan-Romero J, Beuselinck B, Santos M, Rodriguez-Moreno J, Lanillos J, Calsina B . PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma. Int J Cancer. 2019; 146(5):1435-1444. DOI: 10.1002/ijc.32579. View

Chen S, Fisher R, Signs S, Alex Molina L, Shenoy A, Lopez M . Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis. Oncotarget. 2017; 8(31):50476-50488. PMC: 5584153. DOI: 10.18632/oncotarget.9919. View

Liu J, Li D, Luo H, Zhu X . Circular RNAs: The star molecules in cancer. Mol Aspects Med. 2019; 70:141-152. DOI: 10.1016/j.mam.2019.10.006. View

Rodrik-Outmezguine V, Okaniwa M, Yao Z, Novotny C, McWhirter C, Banaji A . Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature. 2016; 534(7606):272-6. PMC: 4902179. DOI: 10.1038/nature17963. View

Madak-Erdogan Z, Band S, Zhao Y, Smith B, Kulkoyluoglu-Cotul E, Zuo Q . Free Fatty Acids Rewire Cancer Metabolism in Obesity-Associated Breast Cancer via Estrogen Receptor and mTOR Signaling. Cancer Res. 2019; 79(10):2494-2510. DOI: 10.1158/0008-5472.CAN-18-2849. View

Caumanns J, Berns K, Wisman G, Fehrmann R, Tomar T, Klip H . Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. Clin Cancer Res. 2018; 24(16):3928-3940. PMC: 6098697. DOI: 10.1158/1078-0432.CCR-17-3060. View

Zhang H, Li X, Yang Y, Zhang Y, Wang H, Zheng X . Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. Hepatology. 2017; 67(6):2271-2286. PMC: 6106789. DOI: 10.1002/hep.29715. View

10.

Guo B, Li D, Du L, Zhu X . piRNAs: biogenesis and their potential roles in cancer. Cancer Metastasis Rev. 2020; 39(2):567-575. DOI: 10.1007/s10555-020-09863-0. View

11.

Yang Y, Chen D, Liu H, Yang K . Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma. Cell Death Dis. 2019; 10(2):41. PMC: 6381212. DOI: 10.1038/s41419-018-1280-8. View

12.

Mossmann D, Park S, Hall M . mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018; 18(12):744-757. DOI: 10.1038/s41568-018-0074-8. View

13.

Unni N, Arteaga C . Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?. JAMA Oncol. 2019; 5(11):1564-1565. DOI: 10.1001/jamaoncol.2019.2525. View

14.

Sen T, Tong P, Diao L, Li L, Fan Y, Hoff J . Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Clin Cancer Res. 2017; 23(20):6239-6253. PMC: 5882197. DOI: 10.1158/1078-0432.CCR-17-1284. View

15.

Dowling R, Topisirovic I, Fonseca B, Sonenberg N . Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2009; 1804(3):433-9. DOI: 10.1016/j.bbapap.2009.12.001. View

16.

Li K, Luo H, Huang L, Luo H, Zhu X . Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int. 2020; 20:16. PMC: 6958913. DOI: 10.1186/s12935-019-1091-8. View

17.

Ye L, Pu C, Tang J, Wang Y, Wang C, Qiu Z . Transmembrane-4 L-six family member-1 (TM4SF1) promotes non-small cell lung cancer proliferation, invasion and chemo-resistance through regulating the DDR1/Akt/ERK-mTOR axis. Respir Res. 2019; 20(1):106. PMC: 6542073. DOI: 10.1186/s12931-019-1071-5. View

18.

Hsieh A, Liu Y, Edlind M, Ingolia N, Janes M, Sher A . The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012; 485(7396):55-61. PMC: 3663483. DOI: 10.1038/nature10912. View

19.

Xie X, Hu H, Tong X, Li L, Liu X, Chen M . The mTOR-S6K pathway links growth signalling to DNA damage response by targeting RNF168. Nat Cell Biol. 2018; 20(3):320-331. PMC: 5826806. DOI: 10.1038/s41556-017-0033-8. View

20.

Neufeld T . TOR-dependent control of autophagy: biting the hand that feeds. Curr Opin Cell Biol. 2009; 22(2):157-68. PMC: 2854204. DOI: 10.1016/j.ceb.2009.11.005. View